ST1571 (Gleevec™) as a paradigm for cancer therapy

被引：211

作者：

Druker, BJ ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Inst Canc, Ctr Leukemia, Portland, OR 97201 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2002年 / 8卷 / 04期

关键词：

D O I：

10.1016/S1471-4914(02)02305-5

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

STI571 (Gleevec(TM), imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.

引用

页码：S14 / S18

页数：5

共 36 条

[1]

ABELSON HT, 1970, CANCER RES, V30, P2213

[2]

[Anonymous], 2001, P AM SOC CLIN ONCOL

[3]

Apperley JF, 2001, BLOOD, V98, p726A

[4]

Blanke CD, 2001, P AM SOC CLIN ONCOL, p1a

[5] CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].

Carroll, M ;

OhnoJones, S ;

Tamura, S ;

Buchdunger, E ;

Zimmermann, J ;

Lydon, NB ;

Gilliland, DG ;

Druker, BJ .

BLOOD, 1997, 90 (12) :4947-4952

[6] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].

DALEY, GQ ;

VANETTEN, RA ;

BALTIMORE, D .

SCIENCE, 1990, 247 (4944) :824-830

[7] The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells [J].

Deininger, MWN ;

Goldman, JM ;

Lydon, N ;

Melo, JV .

BLOOD, 1997, 90 (09) :3691-3698

[8] The molecular biology of chronic myeloid leukemia [J].

Deininger, MWN ;

Goldman, JM ;

Melo, JV .

BLOOD, 2000, 96 (10) :3343-3356

[9] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[10] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

← 1 2 3 4 →